Bibliographies thématiques / Survival outcomes

Littérature scientifique sur le sujet « Survival outcomes »

Auteur : Grafiati
Publié le 10 mars 2023
Mis à jour le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Survival outcomes ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Survival outcomes"

1

Rothstein, Jules M. « Outcomes and Survival ». Physical Therapy 76, no 2 (1 février 1996) : 126–27. http://dx.doi.org/10.1093/ptj/76.2.126.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Buyze, Jozefien, et Els Goetghebeur. « Crossover studies with survival outcomes ». Statistical Methods in Medical Research 22, no 6 (29 juin 2011) : 612–29. http://dx.doi.org/10.1177/0962280211402258.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Steingrimsson, Jon Arni, et Samantha Morrison. « Deep learning for survival outcomes ». Statistics in Medicine 39, no 17 (13 avril 2020) : 2339–49. http://dx.doi.org/10.1002/sim.8542.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Kim, Michelle M., Bouthaina S. Dabaja, Jeffrey Medeiros, Stella Kim, Pamela Allen, Patricia Chevez-Barrios, Dan S. Gombos et Nathan Fowler. « Survival Outcomes of Primary Intraocular Lymphoma ». American Journal of Clinical Oncology 39, no 2 (avril 2016) : 109–13. http://dx.doi.org/10.1097/coc.0000000000000028.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Vallejos, Catalina A., et Mark F. J. Steel. « Bayesian survival modelling of university outcomes ». Journal of the Royal Statistical Society : Series A (Statistics in Society) 180, no 2 (14 juillet 2016) : 613–31. http://dx.doi.org/10.1111/rssa.12211.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Omer, N., K. Boucher et J. DiSario. « SURVIVAL OUTCOMES IN FAMILIAL PANCREATIC CANCER. » Pancreas 29, no 4 (novembre 2004) : 348. http://dx.doi.org/10.1097/00006676-200411000-00090.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Zhang, Eva, Emily Granger, Monique Malouf et Allan R. Glanville. « Survival Outcomes of Redo Lung Transplantation ». Heart, Lung and Circulation 23, no 1 (janvier 2014) : e63. http://dx.doi.org/10.1016/j.hlc.2013.10.079.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Megwalu, Uchechukwu C., et Andrew G. Sikora. « Survival Outcomes in Advanced Laryngeal Cancer ». JAMA Otolaryngology–Head & ; Neck Surgery 140, no 9 (1 septembre 2014) : 855. http://dx.doi.org/10.1001/jamaoto.2014.1671.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Kashkouli, Mohsen Bahmani, Parya Abdolalizadeh, Mitra Oghazian, Yasaman Hadi, Nasser Karimi et Mahya Ghazizadeh. « Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis ». British Journal of Ophthalmology 103, no 10 (4 décembre 2018) : 1460–65. http://dx.doi.org/10.1136/bjophthalmol-2018-312688.

Texte intégral
Résumé :
AimTo report the frequency and factors affecting patients’, globe and vision survivals in rhino-orbito-cerebral mucormycosis (ROCM).MethodsThis is a retrospective study of 63 patients (79 eyes) with biopsy-proven ROCM at a university hospital 2008–2016. Systemic and ophthalmic manifestations, imaging, management and final outcomes were recorded. Globe survival was defined as no exenteration and vision survival as final visual acuity of light perception and more.ResultsMean age was 55.5 (SD 12.9) years with no gender preference. Diabetes was the most common underlying disease (68.3%). Patient survival was observed in 57.1 % (36/63). Presence of frozen eye (OR 4.6), nasal mucosal involvement (OR 7.3) and shorter duration of antifungal therapy (OR 1.03) were significantly associated with lower patient survival. Exenteration did not significantly change the survival. Globe survival was detected in 43% (34/79). Higher white blood cell (WBC) count was associated with a lower globe survival (p=0.02). Vision survival was observed in 25.3% (20/79) in whom younger age was significantly associated with a worse vision survival.ConclusionPatient, globe and vision survivals were 57%, 43% and 25%, respectively. Exenteration did not affect the patients’ survival. While frozen eye and nasal mucosal involvement were significantly associated with a lower survival, higher WBC count significantly increased the risk of exenteration.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Sjölander, Arvid, et Stijn Vansteelandt. « Doubly robust estimation of attributable fractions in survival analysis ». Statistical Methods in Medical Research 26, no 2 (16 décembre 2014) : 948–69. http://dx.doi.org/10.1177/0962280214564003.

Texte intégral
Résumé :
The attributable fraction is a commonly used measure that quantifies the public health impact of an exposure on an outcome. It was originally defined for binary outcomes, but an extension has recently been proposed for right-censored survival time outcomes; the so-called attributable fraction function. A maximum likelihood estimator of the attributable fraction function has been developed, which requires a model for the outcome. In this paper, we derive a doubly robust estimator of the attributable fraction function. This estimator requires one model for the outcome, and one joint model for the exposure and censoring. The estimator is consistent if either model is correct, not necessarily both.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Survival outcomes"

1

Havercroft, William G. « Exploration of marginal structural models for survival outcomes ». Thesis, University of Bristol, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.684750.

Texte intégral
Résumé :
A marginal structural model parameterises the distribution of an outcome given a treatment intervention, where such a distribution is the fundamental probabilistic representation of the causal effect of treatment on the outcome. Causal inference methods are designed to consistently estimate aspects of these causal distributions, in the presence of interference from non-causal associations which typically occur in observational data. One such method, which involves the application of inverse probability of treatment weights, directly targets the parameters of marginal structural models. The asymptotic properties and practical applicability of this method are well established, but little attention has been paid to its finite-sample performance. This is because simulating data from known distributions which are entirely suitable for such investigations generally presents a significant challenge, especially in scenarios where the outcome is survival time. We illuminate these issues, and propose and implement certain solutions, considering separately the cases of static (pre-determined) and dynamic (tailored) treatment interventions. In so doing, we explore both theoretical and practical aspects of marginal structural models for survival outcomes, and the associated inference method.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Cavalli, Maide Maria. « Predicting survival outcomes in Myeloma using surrogate markers ». Doctoral thesis, Università di Catania, 2013. http://hdl.handle.net/10761/1394.

Texte intégral
Résumé :
BACKGROUND: OS should be considered the gold standard before adopting a particular treatment strategy as standard of care in Multiple Myeloma Phase III randomized clinical study but the use of OS as trial endpoint results in long trial duration. The primary objective of our project was to investigate whether there was a required minimum PFS difference between two arms in phase III randomized controlled trials (RCTs) that can be used as a predictor of benefit in overall survival (OS). Secondary objectives were to explore if there was a minimum threshold for VGPR rate and CR rate difference between two arms that will predict OS benefit in RCTs. DESIGN AND METHOD: We performed a PUBMED search to identify potentially relevant randomized controlled trials (RCTs) between January 1992 to January 2012. We also scanned references of abstracts presented at the American Society of Hematology (ASH) between January 2005 to August 2012; this was supplemented by manual searches of others clinical trials. We used both absolute differences in the survival improvement (in months) and response rates between the two arms, as well as proportional improvements for the purpose of analysis. Descriptive statistics were used to summarize the minimum threshold PFS, CR AND VGPR median differences respectively. RESULTS: Assessment of all publications resulted in identification of 75 RCTs. Of the 75 RCTs studied, 17 (22%) had statistically significant improvement in OS on intent to treat analysis (p-value ¡Ü 0.05) .We found that the minimum improvement in median PFS/TTP required to produce a significant improvement in OS was at least 2.5 months or more. This number varied depending on the stage of the disease and the type of treatment . CR improvements appeared to be widely variable, ranging from -5% (arm with survival improvement having worse CR rate by -5%) to 36%, with no particular pattern relative to type of therapy administered and the minimum threshold needed for survival benefit. VGPR rates were reported only in 5 of the 18 trials and therefore could not be accurately computed. CONCLUSION: The current data is still immature to consider PFS improvement a pivotal surrogate marker of OS. We are limited by lack of data on Multiple Myeloma clinical trials showing OS significance.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Lehr, Carli J. « Extremes of Age Decrease Survival After Lung Transplant ». Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case152909506004063.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Ramchandani, Ritesh. « Rank-Based Methods for Survival Data With Multiple Outcomes ». Thesis, Harvard University, 2015. http://nrs.harvard.edu/urn-3:HUL.InstRepos:23845423.

Texte intégral
Résumé :
In clinical studies of survival, additional endpoints on patients may be collected over the course of the study that give additional insight into a treatment's effect. We propose three methods to analyze right censored survival data in the presence of multiple outcomes. In order to make limited parametric assumptions on the data-generating mechanisms, the methods are based on Wilcoxon-type rank statistics. Each method is applied to a recent clinical trial of Ceftriaxone in patients with amyotrophic lateral sclerosis. In chapter 1, we modify the Gehan-Wilcoxon test for survival to account for auxiliary information on intermediate disease states (e.g. progression) that subjects may pass through before failure. We use multi-state modeling to compute expected ranks for each subject conditional on their last observed disease states and censoring time, and these ranks form the basis of our test statistic. Simulations demonstrate that the proposed test can improve power over the log-rank and generalized Wilcoxon tests in some settings while maintaining the nominal type 1 error rate. In chapter 2, we propose an estimator for an accelerated failure time model based on the test statistic proposed in chapter 1. We use the statistic as an estimating equation for a parameter that accelerates the time to each subsequent disease state. The estimator incorporates the intermediate states in a manner relevant to the survival outcome, yielding interpretable treatment and covariate effects that consider the entire trajectory of the patient. Simulations demonstrate that the estimator is unbiased, and that the proposed standard error estimator is near the empirical value. In chapter 3, we aim to assess the treatment effect globally across any types of multiple endpoints. The test we propose is based on a simple scoring mechanism applied to each pair of subjects for each endpoint. The scores for each pair of subjects are then reduced to a summary score, and a rank-sum test is applied to the summary scores. This can be seen as a generalization of several other global rank tests in the literature. Additionally, for certain statistics we describe optimal weighting schemes with respect to statistical power, and provide a method of selecting outcome weights adaptively.
Biostatistics
Styles APA, Harvard, Vancouver, ISO, etc.
5

Meier, Amalia Sophia. « Discrete proportional hazards models for uncertain outcomes / ». Thesis, Connect to this title online ; UW restricted, 2001. http://hdl.handle.net/1773/9579.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Kernell, Kristina. « Cardiac disease in pregnancy and consequences for reproductive outcomes, comorbidity and survival ». Doctoral thesis, Linköpings universitet, Avdelningen för kliniska vetenskaper, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-134854.

Texte intégral
Résumé :
Background Advances in medical treatment during the last 50 years have resulted in more individuals with congenital heart disease (CHD) and Marfan syndrome reaching childbearing age. The substantial physiological changes during pregnancy result in a high-risk situation, and pregnancy is a major concern in women with these conditions. Aims To describe the socio-demographic characteristics, birth characteristics and reproductive patterns of individuals with CHD and women with Marfan syndrome. To investigate obstetric and neonatal outcomes in the firstborn children of individuals with CHD and women with Marfan syndrome. To study long-term cardiovascular outcomes after childbirth in women with Marfan´syndrome. Methods The studies are population-based register studies. The study population in the first paper included all women born between 1973 and 1983 who were alive and resident in Sweden at the age of 13 (494 692 women, of whom 2 216 were women with CHD). In the second paper, the same definition of the study population was chosen, except that it involved all men born between 1973 and 1983 (522 216 men, of whom 2 689 men with CHD). The third and fourth papers involved a study population of all Swedish women born between 1973 and 1993 who were still living in Sweden at age 13. This population consisted of 1 017 538 women, 273 of whom had been diagnosed with Marfan syndrome. Results and conclusions The individuals studied were more often born preterm, and were small-for-gestational age babies. They were more likely to have been born by cesarean section. In women with CHD, these characteristics were repeated in their firstborn children. No increased risks were found in children of men with CHD or in children of women with Marfan syndrome. There was no increased risk of aortic dissection in women with Marfan syndrome during pregnancy compared to women with Marfan syndrome who did not give birth. Higher frequencies of cardiac arrhythmia and valvular heart disease were found after childbirth in women with Marfan syndrome. Pregnancy in women with CHD is a high-risk situation associated with increased risk of adverse neonatal outcomes for the expected child. Pregnancy in women without CHD, but where the father has CHD is not so associated with increased risk of adverse obstetric or neonatal outcomes. Pregnancy in women with Marfan syndrome is not associated with adverse outcomes for the expected child.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Dodd, Susanna. « Modelling departure from randomised treatment in randomised controlled trials with survival outcomes ». Thesis, University of Liverpool, 2014. http://livrepository.liverpool.ac.uk/2006887/.

Texte intégral
Résumé :
Randomised controlled trials are considered the gold standard study design, as random treatment assignment provides balance in prognosis between treatment arms and protects against selection bias. When trials are subject to departures from randomised treatment, however, simple but naïve statistical methods that purport to estimate treatment efficacy, such as per protocol or as treated analyses, fail to respect this randomisation balance and typically introduce selection bias. This bias occurs because departure from randomised treatment is often clinically indicated, resulting in systematic differences between patients who do and do not adhere to their assigned intervention. There exist more appropriate statistical methods to adjust for departure from randomised treatment but, as demonstrated by a review of published trials, these are rarely employed, primarily due to their complexity and unfamiliarity. The focus of this research has been to explore, explain, demonstrate and compare the use of causal methodologies in the analysis of trials, in order to increase the accessibility and comprehensibility by non-specialist analysts of the available, but somewhat technical, statistical methods to adjust for treatment deviations. An overview of such methods is presented, intended as an aid to researchers new to the field of causal inference, with an emphasis on practical considerations necessary to ensure appropriate implementation of techniques, and complemented by a number of guidance tools summarising the necessary clinical and statistical considerations when carrying out such analyses. Practical demonstrations of causal analysis techniques are then presented, with existing methods extended and adapted to allow for complexities arising from the trial scenarios. A particular application from epilepsy demonstrates the impact of various statistical factors when adjusting for skewed time-varying confounders and different reasons for treatment changes on a complicated time to event outcome, including choice of model (pooled logistic regression versus Cox models for inverse probability of censoring weighting methods, compared with a rank-preserving structural failure time model), time interval (for creating panel data for time-varying confounders and outcome), confidence interval estimation method (standard versus bootstrapped) and the considerations regarding use of spline variables to estimate underlying risk in pooled logistic regression. In this example, the structural failure time model is severely limited by its restriction on the types of treatment changes that can be adjusted for; as such, the majority of treatment changes are necessarily censored, introducing bias similar to that in a per protocol analysis. With inverse probability weighting adjustment, as more treatment changes and confounders are accounted for, treatment effects are observed to move further away from the null. Generally, Cox models seemed to be more susceptible to changes in modelling factors (confidence interval estimation, time interval and confounder adjustment) and displayed greater fluctuations in treatment effect than corresponding pooled logistic regression models. This apparent greater stability of logistic regression, even when subject to severe overfitting, represents a major advantage over Cox modelling in this context, countering the inherent complications relating to the fitting of spline variables. This novel application of complex methods in a complicated trial scenario provides a useful example for discussion of typical analysis issues and limitations, as it addresses challenges that are likely to be common in trials featuring problems with nonadherence. Recommendations are provided for analysts when considering which of these analysis methods should be applied in a given trial setting.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Kitajima, Toshihiro. « Impact of graft thickness reduction of left lateral segment on outcomes following pediatric living donor liver transplantation ». Kyoto University, 2019. http://hdl.handle.net/2433/242356.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Rahman, M. S. « Validation measures for prognostic models for independent and correlated binary and survival outcomes ». Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1367069/.

Texte intégral
Résumé :
Prognostic models are developed to guide the clinical management of patients or to assess the performance of health institutions. It is essential that performances of these models are evaluated using appropriate validation measures. Despite the proposal of several validation measures for survival outcomes, it is still unclear which measures should be generally used in practice. In this thesis, a simulation study was performed to investigate a range of validation measures for survival outcomes in order to make practical recommendations regarding their use. Measures were evaluated with respect to their robustness to censoring and their sensitivity to the omission of important predictors. Based on the simulation results, from the discrimination measures, Gonen and Heller's K statistic can be recommended for validating a survival risk model developed using the Cox proportional hazards model, since it is both robust to censoring and reasonably sensitive to predictor omission. Royston and Sauerbrei's D statistic can be recommended provided that the distribution of the prognostic index is approximately normal. Harrell's C-index was affected by censoring and cannot be recommended for use with data with more than 30% censoring. The calibration slope can be recommended as a measure of calibration since it is not affected by censoring. The measures of predictive accuracy and explained variation (Graf et al's integrated Brier Score and its R-square version, and Schemper and Henderson's V) cannot be recommended due to their poor performance in the presence of censored data. In multicentre studies patients are typically clustered within centres and are likely to be correlated. Typically, random effects logistic and frailty models are fitted to clustered binary and survival outcomes, respectively. However, limited work has been done to assess the predictive ability of these models. This research extended existing validation measures for independent data, such as the C-index, D statistic, calibration slope, Brier score, and the K statistic for use with random effects/frailty models. Two approaches: the `overall' and `pooled cluster-specific' are proposed. The `overall' approach incorporates comparisons of subjects both within-and between-clusters. The `pooled cluster-specific' measures are obtained by pooling the cluster-specific estimates based on comparisons of subjects within each cluster; the pooling is achieved using a random effects summary statistics method. Each approach can produce three different values for the validation measures, depending on the type of predictions: conditional predictions using the estimates of the random effects or setting these as zero and marginal predictions by integrating out the random effects. Their performances were investigated using simulation studies. The `overall' measures based on the conditional predictions including the random effects performed reasonably well in a range of scenarios and are recommended for validating models when using subjects from the same clusters as the development data. The measures based on the marginal predictions and the conditional predictions that set the random effects to be zero were biased when the intra-cluster correlation was moderate to high and can be used for subjects in new clusters when the intra-cluster correlation coefficient is less than 0.05. The `pooled cluster-specific' measures performed well when the clusters had reasonable number of events. Generally, both the `overall' and `pooled' measures are recommended for use in practice. In choosing a validation measure, the following characteristics of the validation data should be investigated: the level of censoring (for survival outcome), the distribution of the prognostic index, whether the clusters are the same or different to those in the development data, the level of clustering and the cluster size.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Underhill, Andrea T. « Gender differences in traumatic brain injury outcomes survival, functional independence, and employment status / ». Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2008. https://www.mhsl.uab.edu/dt/2008p/underhill.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Livres sur le sujet "Survival outcomes"

1

Rodriguez, M. Alma, Ronald S. Walters et Thomas W. Burke, dir. 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. New York, NY : Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-5197-6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

60 years of survival outcomes at the University of Texas M.D. Anderson Cancer Center. New York : Springer, 2012.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Tibandebage, Paula. Empowering nurses to improve maternal health outcomes : Paper 1 from the Ethics, Payments, and Maternal Survival project. Dar es Salaam : REPOA, 2013.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Office, General Accounting. Cancer survival : An international comparison of outcomes : report to the Ranking Minority Member, Subcommittee on Health, Committee on Ways and Means, House of Representatives. Washington, D.C : The Office, 1994.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Jaigobin, Cheryl S. Survival, stroke recurrence and functional outcome after lacunar stroke. Ottawa : National Library of Canada, 2001.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

G, Taktak Azzam F., et Fischer Anthony C, dir. Outcome prediction in cancer. Amsterdam : Elsevier, 2007.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Schulz, Kenneth F. Reproductive tract infections : Impact on pregnancy outcome and child survival. Atlanta, Ga : Centers for Disease Control, 1991.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Allan, Parker, dir. A strange outcome : The remarkable survival story of a Polish child. Auckland, N.Z : Penguin Books, 2004.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

He breathes again : A true and amazing narrative of survival from an incurable lung disease. [Sri Lanka} : publisher not identified, 2015.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Miller, C. Arden. Maternal health and infant survival : An analysis of medical and social services to pregnant women, newborns, and their families in ten European countries, with implications for policy and practice in the United States : a study from the Child Health Outcomes Project, Department of Maternal and Child Health, School of Public Health, the University of North Carolina. Washington, D.C : National Center for Clinical Infant Programs, 1987.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Chapitres de livres sur le sujet "Survival outcomes"

1

Flaatten, Hans. « Outcomes After Intensive Care : Survival ». Dans The Very Old Critically Ill Patients, 369–80. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94133-8_24.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Schreiber, Martin J. « Survival Outcomes with Peritoneal Dialysis ». Dans Applied Peritoneal Dialysis, 273–300. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70897-9_21.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Xu, Yizhe, Nikolaos Ignatiadis, Erik Sverdrup, Scott Fleming, Stefan Wager et Nigam Shah. « Treatment Heterogeneity with Survival Outcomes ». Dans Handbook of Matching and Weighting Adjustments for Causal Inference, 445–82. Boca Raton : Chapman and Hall/CRC, 2023. http://dx.doi.org/10.1201/9781003102670-21.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Awadallah, Michael, Kurt Nisi et Ketan J. Patel. « Factors Affecting Response and Survival in Radiotherapy ». Dans Improving Outcomes in Oral Cancer, 105–15. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-30094-4_8.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Moore, Dirk F. « Multiple Survival Outcomes and Competing Risks ». Dans Use R !, 113–35. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31245-3_9.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Yeates, K. E., et P. G. Blake. « Comparing Survival Outcomes in Peritoneal Dialysis and Hemodialysis ». Dans Nolph and Gokal’s Textbook of Peritoneal Dialysis, 39–50. Boston, MA : Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-78940-8_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Carrasquinha, Eunice, André Veríssimo, Marta B. Lopes et Susana Vinga. « Network-Based Variable Selection for Survival Outcomes in Oncological Data ». Dans Bioinformatics and Biomedical Engineering, 550–61. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45385-5_49.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Tan, Q., M. Thomassen, KM Jochumsen, O. Mogensen, K. Christensen et TA Kruse. « Gene Selection for Predicting Survival Outcomes of Cancer Patients in Microarray Studies ». Dans Advances in Computer and Information Sciences and Engineering, 405–9. Dordrecht : Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-8741-7_73.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

van Kuijk, Sander M. J., Frank J. W. M. Dankers, Alberto Traverso et Leonard Wee. « Preparing Data for Predictive Modelling ». Dans Fundamentals of Clinical Data Science, 75–84. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-99713-1_6.

Texte intégral
Résumé :
AbstractThis is the first chapter of five that cover an introduction to developing and validating models for predicting outcomes for the individual patient. Such prediction models can be used for predicting the occurrence or recurrence of an event, or of the most likely value on a continuous outcome. We will mainly focus on the prediction of binary outcomes, such as the occurrence of a complication, recurrence of disease, the presence of metastases, remission, survival, etc. This chapter deals with the selection of an appropriate study design for a study on prediction, and on methods to manipulate the data before the statistical modelling can begin.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Jacoby, Elad, Nicola Gökbuget et Arnon Nagler. « Adult Acute Lymphoblastic Leukaemia ». Dans The EBMT/EHA CAR-T Cell Handbook, 61–66. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_11.

Texte intégral
Résumé :
AbstractALL is a malignancy of lymphoid progenitor cells, with a bimodal incidence, peaking in early childhood and in older age. In children, ALL tends to have an excellent prognosis, with more than 85% of patients achieving long-term survival. The outcome of younger adults has improved considerably as well. However, overall survival decreases with age (Dores et al. 2012), partially due to the different genetic background of adult ALL, with a higher proportion of Philadelphia chromosome-positive (Ph+) ALL and Ph-like and KMT2A rearrangements in comparison to childhood ALL (Iacobucci and Mullighan 2017). The introduction of paediatric-inspired regimens has improved outcomes in adults, but these regimens are less tolerated in older patients (Curran and Stock 2015).
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Survival outcomes"

1

Ghosh, Ananya, Namrata Das, Sudip Mondal et Srikanta Patnaik. « Kaplan-Meier Survival Estimator Analysis of Patient Data ». Dans 2021 Smart City Challenges & Outcomes for Urban Transformation (SCOUT). IEEE, 2021. http://dx.doi.org/10.1109/scout54618.2021.00059.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Occhipinti, Annalisa, et Claudio Angione. « A Computational Model of Cancer Metabolism for Personalised Medicine ». Dans Building Bridges in Medical Science 2021. Cambridge Medicine Journal, 2021. http://dx.doi.org/10.7244/cmj.2021.03.001.3.

Texte intégral
Résumé :
Cancer cells must rewrite their ‘‘internal code’’ to satisfy the demand for growth and proliferation. Such changes are driven by a combination of genetic (e.g., genes’ mutations) and non-genetic factors (e.g., tumour microenvironment) that result in an alteration of cellular metabolism. For this reason, understanding the metabolic and genomic changes of a cancer cell can provide useful insight on cancer progression and survival outcomes. In our work, we present a computational framework that uses patient-specific data to investigate cancer metabolism and provide personalised survival predictions and cancer development outcomes. The proposed model integrates patient-specific multi-omics data (i.e., genomic, metabolomic and clinical data) into a metabolic model of cancer to produce a list of metabolic reactions affecting cancer progression. Quantitative and predictive analysis, through survival analysis and machine learning techniques, is then performed on the list of selected reactions. Since our model performs an analysis of patient-specific data, the outcome of our pipeline provides a personalised prediction of survival outcome and cancer development based on a subset of identified multi-omics features (genomic, metabolomic and clinical data). In particular, our work aims to develop a computational pipeline for clinicians that relates the omic profile of each patient to their survival probability, based on a combination of machine learning and metabolic modelling techniques. The model provides patient-specific predictions on cancer development and survival outcomes towards the development of personalised medicine.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Moya Alvarez, Virginia, Ismael Ali Garcia, Julio Hernandez Vazquez, Carmen Matesanz Ruiz, Jose María Bellon Cano, María Jesús Buendia Garcia et Javier de Miguel Diez. « Bronchial hyperresponsiveness in COPD : Impact on survival outcomes ». Dans ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1598.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

George, Anne, Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy et Abraham Peedicayil. « Outcomes of carcinosarcoma of the uterus ». Dans 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685334.

Texte intégral
Résumé :
Objectives: To evaluate the outcome of women with uterine carcinosarcoma. Methods: The medical records of all patients admitted with uterine carcinosarcoma between January 2012 and October 2015 were reviewed. Baseline characteristics were compared and survival was calculated using Kaplan Meier method and compared using log rank test. Results: The total number of uterine malignancies operated in our centre over this time period was 247 of which 33 were sarcomas (13%). Median age of presentation was 56 years (21-77 years). Most women were postmenopausal (76%) and 46% of them presented with post menopausal bleeding.There were 16 carcinosarcomas of the uterus. Eight presented at Stage 1 (50%) and the remaining 8 in stage III or IV. All patients had TAH/BSO but only 15 had omentectomy and 12 had pelvic and para-aortic lymphadenectomy. Adjuvant treatment was given only to 10 (63%). Seven patients had expired at the time of follow up. The mean survival was 502 days (304-699) with a median of 284 days. Patients who received adjuvant therapy did better compared to those who did not (p=0.05). Conclusions: Carcinosarcomas are aggressive tumours and the optimal therapy is yet to be determined. Adequate surgical staging followed by adjuvant therapy improves survival.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Zhang, Yuanyang, Richard Jiang et Linda Petzold. « Survival Topic Models for Predicting Outcomes for Trauma Patients ». Dans 2017 IEEE 33rd International Conference on Data Engineering (ICDE). IEEE, 2017. http://dx.doi.org/10.1109/icde.2017.219.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Ackall, Feras Y., Ian Barak, Khalil Issa, Jordan Teitelbaum, David W. Jang, Sin-Ho Jung et Ralph Abi Hachem. « Survival Outcomes in Sinonasal Poorly Differentiated Squamous Cell Carcinoma ». Dans 30th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1702309.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Tovey, S., J. Edwards, S. Brown, E. Mallon et J. Doughty. « Poor Survival Outcomes in Elderly HER2 Positive Breast Cancer Patients. » Dans Abstracts : Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009 ; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2010.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Wang, C., B. Lester, L. Huang, S. Sun et JJ Ko. « 132 Survival outcomes in cervical cancer : what factors affect recurrence ? » Dans ESGO 2021 Congress. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-esgo.11.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Khorsheed, Lana, Iain Lawrie, Sara Winward, Karen Redmond, Donna Eaton, David Healy, Lars Nolke, Seyed Javadpour, Jim Egan et Jana Kleinerova. « Outcomes and survival in alpha1-antitrypsin deficiency post lung transplantation ». Dans ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2599.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, Biswajit Dubashi, Smita Kayal, Latha Chaturvedula, Dasari Papa, Prasanth Penumadu, Narendran Krishnamoorthy et Divya B. Thumaty. « Epithelial Ovarian Cancer : Real-World Outcomes ». Dans Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Texte intégral
Résumé :
Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find factors affecting progression-free survival (PFS) and overall survival (OS) with first-line treatment in EOC. Materials and Methods We conducted a single-center retrospective study. We screened all the patients diagnosed with ovarian cancer from January 2015 till December 2019. We locked data in August 2019. Eligible patients were histologically confirmed EOC who underwent primary cytoreduction or received more than or equal to two cycles of chemotherapy or both. Patients who had received first-line treatment at another hospital were excluded. Results Patients demographics and clinical characteristics: between January 5, 2015 to August 31, 2019, 435 patients with a diagnosis of ovarian malignancy were registered at our center. Among them, 406 (82%) had EOC, 290 (64%) newly diagnosed, and fulfilling eligibility criteria were included in the final analysis. The median age of the cohort was 53 years (range: 21–89 years) and 157 patients (54%) were >50 years of age (the Eastern Oncology Cooperative Group Performance status was ≥ 2 in 124 patients [43%]; median duration of symptoms was 3 months; and stage III/IV: 240 [83%]). Grading of the tumor was available in 240 patients of which 219 (91%) were of high grade. Subtyping was available in 272 patients (94%) of which the serous subtype was the most common constituting 228 patients (79%).Treatment Most patients received chemotherapy (n = 283 [98%]) as the first modality of treatment (neoadjuvant/adjuvant and palliative). As neoadjuvant (NACT) in 130 patients (45%) and as adjuvant following surgery in 81 patients (29%). The most common chemotherapy regimen was a combination of carboplatin and paclitaxel in 256 patients (88%). Among 290 patients 218 (75%) underwent cytoreductive surgery. Among them, optimal cytoreduction was achieved in 108 patients (52%). Optimal cytoreduction rate (OCR) with upfront surgery and after NACT was 44 and 53%, respectively (Chi-square test: 0.86; p = 0.35).Survival The median follow-up of the study was 17 months (range: 10–28 months) and it was 20 months (range: 12–35 months) for patients who were alive. At last, follow-up, 149 patients (51%) had progressed and 109 (38%) died. The estimated median PFS and OS were 19 months (95% CI: 16.1–21.0) and 39 months (95% CI: 29.0–48.8), respectively. On multivariate analysis, primary surgery (HR: 0.1, 95% CI: 0.06–0.21; p-value: <0.001) and early-stage disease (HR: 0.2, 95% CI: 0.1–0.6; p-value 0.04) were associated with superior PFS and primary surgery (HR: 0.1, 95% CI: 0.09–0.2; p-value: <0.001) was associated with superior OS. Conclusion Primary surgery (upfront or interval) was associated with improved survival. Newer agents like bevacizumab, poly-ADP (adenosine diphosphate)-ribose polymerase inhibitors and HIPEC should be incorporated precisely into first line of therapy to improve outcomes.
Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Survival outcomes"

1

Meng, Wenwen, Haiyan Shi, Jie Liu, Xiaohui Ge, Yafeng Xu, Shiqi Shan, Lin Wang, Juwei Liu, Lin Zha et Jun Niu. NF-κB expression and survival outcomes in gastric cancer : A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, août 2020. http://dx.doi.org/10.37766/inplasy2020.8.0037.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Mao, Yifeng, Mingqiu Hu, Gaowei Yang, Erke Gao et Wangwang Xu. Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases : a systematic meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, juin 2022. http://dx.doi.org/10.37766/inplasy2022.6.0017.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Dioguardi, Mario. The Prognostic Role of miR-195 and miR-34 in HNSCC : Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, avril 2022. http://dx.doi.org/10.37766/inplasy2022.4.0150.

Texte intégral
Résumé :
Review question / Objective: The PICO question was as follows: What is the RR and HR in the prognostic survival indices among HNSCC patients with high tissue miR-195 expression compared to those with low expression? The different points studied were: (P) participants (patients with HNSCC), (I) intervention (impaired expression of miR-195in HNSCC), (C) control (patients with HNSCC who have low expression of miR-195), ( O) outcome (difference in death risk of survival prognosis between patients with low and high miR-195 expression in HNSCC). Main outcome(s): The main outcomes are HR and the RR on the prognostic indices of survival including: OS, DFS, CSS and PFS.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Zhu, Yi-Bing, Yan Yao, Yuan Xu et Hui-Bin Huang. Nitrogen balance and Outcomes in Critically Ill Patients : A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mai 2022. http://dx.doi.org/10.37766/inplasy2022.5.0134.

Texte intégral
Résumé :
Review question / Objective: This study aimed to evaluate the impact of Nitrogen balance (NB) on prognosis in such a patient population. Condition being studied: Nitrogen balance and Outcomes in Critically Ill Patients. Eligibility criteria: 1) The study focused on the association between NB level and the mortality risk in adult (≥18 years old) patients; 2) The outcome data included any reporting form of survival data that could be extracted; and 3) The study design was limited to cohort, case-control, or RCT design.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Zeng, Linyan, Junwei Su, Wenqi Qiu, Xuehang Jin, Yunqing Qiu et Wei Yu. Survival Outcomes and Safety of PD-1/PD-L1 Inhibitors for Unresectable Hepatocellular Carcinoma : Result from Phase III Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, janvier 2022. http://dx.doi.org/10.37766/inplasy2022.1.0067.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

He, Yazhou, Chi Shu, Junning Liu, Jun Huang, Ziqiang Wang et Shuai Jin. Effect of perineural invasion on survival outcomes of colorectal cancer patients undergoing adjuvant chemotherapy : A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, avril 2022. http://dx.doi.org/10.37766/inplasy2022.4.0106.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Williams, Thomas. Cell Biology Board Game : Cell Survival (School Version). University of Dundee, 2022. http://dx.doi.org/10.20933/100001270.

Texte intégral
Résumé :
Cells are the smallest units of life. The environment around cells is always changing. Cells need to adapt to survive. This curriculum linked game and lesson plan introduces the world of cells to pupils 8-13. But can they keep their cells alive? This is a guide to how the cell survival resources can be used in a lesson and can be adapted as the teacher sees fit to do so. This lesson is aimed at 8-13 year olds, and fits into an hour long session. The Cell Survival Game has been adapted for both home use and for use in the classroom, and is accompanied by a series of videos. Learning Outcomes – Cells are the smallest unit of life – There are many different types of cells, and some examples of cell types – Cells experience many dangers, and some examples of dangers – How cells notice and defend themselves against dangers Links to the Curriculum – Health and Wellbeing: I am developing my understanding of the human body – Languages: I can find specific information in a straight forward text (book and instructions) to learn new things, I discover new words and phrases (relating to cells) – Mathematics: I am developing a sense of size and amount (by using the dice), I am exploring number processes (addition and subtraction) and understand they represent quantities (steps to finish line), I am learning about measurements (cell sizes) and am exploring patterns (of cell defences against dangers) – Science: I am learning about biodiversity (different types of microbes), body systems, cells and how they work. – Technology: I am learning about new technologies (used to understand how cells work).
Styles APA, Harvard, Vancouver, ISO, etc.
8

Zhang, Yong. Efficacy and safety of corticosteroid therapy in patients with cardiac arrest : a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, janvier 2023. http://dx.doi.org/10.37766/inplasy2023.1.0014.

Texte intégral
Résumé :
Review question / Objective: Our goal was to assess the effect of primary treatment outcome (overall survival rate at hospital discharge, rate of sustained ROSC) and secondary outcomes (favorable neurological outcomes at hospital discharge and adverse events including hyperglycemia, insulin infusion, hypernatremia, infection, gastrointestinal bleeding, new or changing antibiotics, paresis, renal failure). Information sources: Two researchers (Zhou FW and Liu C) independently searched the PubMed, Embase, The Cochrane Library, Web of Science and China National Knowledge Internet (CNKI) databases from inception to 11 October, 2022 by using medical subject headings (MeSH), Emtree, and text word with no language limitations.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Wu, Siyin, Yunlong Wang et Ke Ma. Can dexmedetomidine improve survival outcomes in septic patients with mechanical ventilation compared with other sedatives ? : A meta-analysis of a randomized controlled trial. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2021. http://dx.doi.org/10.37766/inplasy2021.9.0092.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Marenco-Hillembrand, Lina, Michael A. Bamimore, Julio Rosado-Philippi, Blake Perdikis, David N. Abarbanel, Alfredo Quinones-Hinojosa, Kaisorn L. Chaichana et Wendy J. Sherman. The Evolving Landscape of Leptomeningeal Cancer from Solid Tumors : A Systematic Review of Clinical Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, décembre 2022. http://dx.doi.org/10.37766/inplasy2022.12.0112.

Texte intégral
Résumé :
Review question / Objective: Among adult patients with leptomeningeal carcinomatosis from solid tumors (population) treated with chemotherapy, targeted therapy, or immunotherapy (intervention and comparator) what are the differences in overall survival (OS) and progression-free survival (PFS) and treatment response based on clinical trial outcomes? Eligibility criteria: Included articles reported 1) human subjects ≥ 18 years 2) diagnosis of leptomeningeal carcinomatosis from solid tumors confirmed by imaging or cerebrospinal fluid (CSF) cytology and clinical or neurological symptoms 3) clinical trials 4) with either PFS or MOS outcomes listed. Book chapters, case reports, review articles, observational studies, ed-itorials, and publications of leptomeningeal cancer from hematological tumors and studies consisting solely of pediatric patients were excluded from the analysis.
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Survival outcomes » pour d’autres types de sources :
Articles de revues Thèses Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie